Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|HER2+ Breast Cancer
Interventions: DRUG: BKM120|DRUG: Trastuzumab|DRUG: Capecitabine
Sponsor: Novartis Pharmaceuticals